Literature DB >> 15222689

Association of apolipoprotein E and myeloperoxidase genotypes to clinical course of familial and sporadic multiple sclerosis.

B Zakrzewska-Pniewska1, M Styczynska, A Podlecka, R Samocka, B Peplonska, M Barcikowska, H Kwiecinski.   

Abstract

The importance of apolipoprotein E (ApoE) and myeloperoxidase (MPO) genotypes in the clinical characteristics of multiple sclerosis (MS) has been recently emphasized. In a large group of Polish patients we have tested the hypothesis that polymorphism in ApoE and MPO genes may influence the course of the disease. Genotypes were determined in 117 MS patients (74 females and 43 males; 99 sporadic and 18 familial cases) with mean EDSS of 3.6, mean age of 44. 1 years, mean duration of the disease 12.8 years and mean onset of MS at 31.2 years, and in 100 healthy controls. The relationship between ApoE and MPO genes' polymorphism and the MS activity as well as the defect of remyelination (diffuse demyelination) and brain atrophy on MRI were analysed. The ApoE epsilon4 allele was not related to the disease course or the ApoE epsilon2 to the intensity of demyelination on MRI. The genotype MPO G/G was found in all familial MS and in 57% (56/99) of sporadic cases. This genotype was also related to more pronounced brain atrophy on MRI. The MPO G/G subpopulation was characterized by a significantly higher proportion of patients with secondary progressive MS (P < 0.05) and by a higher value of EDSS. According to our results the MPO G allele is frequently found (in 96% of cases) among Polish patients with MS. More severe nervous tissue damage in the MPO G/G form can be explained by the mechanism of accelerated oxidative stress. It seems that MPO G/G genotype may be one of the genetic factors influencing the progression rate of disability in MS patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15222689     DOI: 10.1191/1352458504ms1015oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  9 in total

1.  Demyelinating diseases: myeloperoxidase as an imaging biomarker and therapeutic target.

Authors:  Reza Forghani; Gregory R Wojtkiewicz; Yinian Zhang; Daniel Seeburg; Benjamin R M Bautz; Benjamin Pulli; Andrew R Milewski; Wendy L Atkinson; Yoshiko Iwamoto; Elizabeth R Zhang; Martin Etzrodt; Elisenda Rodriguez; Clinton S Robbins; Filip K Swirski; Ralph Weissleder; John W Chen
Journal:  Radiology       Date:  2012-03-21       Impact factor: 11.105

2.  Upregulation of CSPG3 accompanies neuronal progenitor proliferation and migration in EAE.

Authors:  Mir Sajad; Jamil Zargan; Raman Chawla; Sadiq Umar; Haider A Khan
Journal:  J Mol Neurosci       Date:  2010-11-25       Impact factor: 3.444

Review 3.  Opportunities for Molecular Imaging in Multiple Sclerosis Management: Linking Probe to Treatment.

Authors:  Aline M Thomas; Frederik Barkhof; Jeff W M Bulte
Journal:  Radiology       Date:  2022-04-26       Impact factor: 29.146

Review 4.  Myeloperoxidase: A new player in autoimmunity.

Authors:  Anna Strzepa; Kirkwood A Pritchard; Bonnie N Dittel
Journal:  Cell Immunol       Date:  2017-05-10       Impact factor: 4.868

Review 5.  Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making.

Authors:  Violaine K Harris; Saud A Sadiq
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

6.  Myeloperoxidase-targeted imaging of active inflammatory lesions in murine experimental autoimmune encephalomyelitis.

Authors:  John W Chen; Michael O Breckwoldt; Elena Aikawa; Gloria Chiang; Ralph Weissleder
Journal:  Brain       Date:  2008-01-29       Impact factor: 13.501

7.  Genetic variation in the myeloperoxidase gene and cognitive impairment in multiple sclerosis.

Authors:  I Manna; P Valentino; A La Russa; F Condino; R Nisticò; M Liguori; A Clodomiro; V Andreoli; D Pirritano; R Cittadella; A Quattrone
Journal:  J Negat Results Biomed       Date:  2006-02-27

8.  Association of APOE Serum Levels and APOE ε2, ε3, and ε4 Alleles with Optic Neuritis.

Authors:  Liucija Momkute; Alvita Vilkeviciute; Greta Gedvilaite; Gabriele Dubinskaite; Loresa Kriauciuniene; Rasa Liutkeviciene
Journal:  Genes (Basel)       Date:  2022-07-01       Impact factor: 4.141

9.  Pharmacological Inhibition of STAT3 by Stattic Ameliorates Clinical Symptoms and Reduces Autoinflammation in Myeloid, Lymphoid, and Neuronal Tissue Compartments in Relapsing-Remitting Model of Experimental Autoimmune Encephalomyelitis in SJL/J Mice.

Authors:  Khalid Alhazzani; Sheikh F Ahmad; Naif O Al-Harbi; Sabry M Attia; Saleh A Bakheet; Wedad Sarawi; Saleh A Alqarni; Mohammad Algahtani; Ahmed Nadeem
Journal:  Pharmaceutics       Date:  2021-06-22       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.